Evarrest

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin
MedicineHumanWithdrawn

Danish is available via eTranslation, the European Commission's machine translation service.

Translate to Danish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 November 2017, the European Commission withdrew the marketing authorisation for Evarrest (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Omrix Biopharmaceuticals N. V., which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons. 

Evarrest was granted marketing authorisation in the EU on 25 September 2013 for the treatment of haemostasis and as an adjunct to haemostasis in bleeding.

The European Public Assessment Report (EPAR) for Evarrest is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (597.14 KB - PDF)

Vis

español (ES) (515.07 KB - PDF)

Vis

čeština (CS) (578.52 KB - PDF)

Vis

dansk (DA) (518.89 KB - PDF)

Vis

Deutsch (DE) (516.28 KB - PDF)

Vis

eesti (ET) (518.26 KB - PDF)

Vis

ελληνικά (EL) (600.8 KB - PDF)

Vis

français (FR) (518 KB - PDF)

Vis

hrvatski (HR) (535.13 KB - PDF)

Vis

italiano (IT) (514.66 KB - PDF)

Vis

latviešu (LV) (593.61 KB - PDF)

Vis

lietuvių (LT) (538.4 KB - PDF)

Vis

magyar (HU) (571.9 KB - PDF)

Vis

Malti (MT) (577.35 KB - PDF)

Vis

Nederlands (NL) (514.67 KB - PDF)

Vis

polski (PL) (576.8 KB - PDF)

Vis

português (PT) (536.9 KB - PDF)

Vis

română (RO) (1020.06 KB - PDF)

Vis

slovenčina (SK) (100.5 KB - PDF)

Vis

slovenščina (SL) (567.85 KB - PDF)

Vis

suomi (FI) (513.9 KB - PDF)

Vis

svenska (SV) (514.56 KB - PDF)

Vis

Product information

български (BG) (1.55 MB - PDF)

Vis

español (ES) (896.44 KB - PDF)

Vis

čeština (CS) (1.51 MB - PDF)

Vis

dansk (DA) (813.54 KB - PDF)

Vis

Deutsch (DE) (845.01 KB - PDF)

Vis

eesti (ET) (787.41 KB - PDF)

Vis

ελληνικά (EL) (1.55 MB - PDF)

Vis

français (FR) (818.58 KB - PDF)

Vis

hrvatski (HR) (898.08 KB - PDF)

Vis

italiano (IT) (816.34 KB - PDF)

Vis

latviešu (LV) (1.31 MB - PDF)

Vis

lietuvių (LT) (910.1 KB - PDF)

Vis

magyar (HU) (1.15 MB - PDF)

Vis

Malti (MT) (1.31 MB - PDF)

Vis

Nederlands (NL) (827.81 KB - PDF)

Vis

polski (PL) (1.32 MB - PDF)

Vis

português (PT) (818.67 KB - PDF)

Vis

română (RO) (934.43 KB - PDF)

Vis

slovenčina (SK) (1.32 MB - PDF)

Vis

slovenščina (SL) (1.25 MB - PDF)

Vis

suomi (FI) (923.42 KB - PDF)

Vis

svenska (SV) (864.7 KB - PDF)

Vis

Íslenska (IS) (877.78 KB - PDF)

Vis

norsk (NO) (860 KB - PDF)

Vis
Latest procedure affecting product information:II/0027/G
15/11/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (496.48 KB - PDF)

Vis

español (ES) (460.12 KB - PDF)

Vis

čeština (CS) (486.03 KB - PDF)

Vis

dansk (DA) (460.06 KB - PDF)

Vis

Deutsch (DE) (459.93 KB - PDF)

Vis

eesti (ET) (459.94 KB - PDF)

Vis

ελληνικά (EL) (496.65 KB - PDF)

Vis

français (FR) (459.86 KB - PDF)

Vis

hrvatski (HR) (472.28 KB - PDF)

Vis

italiano (IT) (459.91 KB - PDF)

Vis

latviešu (LV) (489.48 KB - PDF)

Vis

lietuvių (LT) (474.86 KB - PDF)

Vis

magyar (HU) (484.42 KB - PDF)

Vis

Malti (MT) (490.05 KB - PDF)

Vis

Nederlands (NL) (459.69 KB - PDF)

Vis

polski (PL) (489.07 KB - PDF)

Vis

português (PT) (459.81 KB - PDF)

Vis

română (RO) (930.92 KB - PDF)

Vis

slovenčina (SK) (29.59 KB - PDF)

Vis

slovenščina (SL) (483.95 KB - PDF)

Vis

suomi (FI) (460.2 KB - PDF)

Vis

svenska (SV) (459.88 KB - PDF)

Vis

Íslenska (IS) (460 KB - PDF)

Vis

norsk (NO) (459.61 KB - PDF)

Vis

Product details

Name of medicine
Evarrest
Active substance
  • human fibrinogen
  • human thrombin
International non-proprietary name (INN) or common name
  • human fibrinogen
  • human thrombin
Therapeutic area (MeSH)
Hemostasis
Anatomical therapeutic chemical (ATC) code
B02BC30

Pharmacotherapeutic group

Local hemostatics

Therapeutic indication

Supportive treatment in adult surgery where standard surgical techniques are insufficient (see section 5.1):

- for improvement of haemostasis.

Authorisation details

EMA product number
EMEA/H/C/002515
Marketing authorisation holder
Omrix Biopharmaceuticals N. V.

Leonardo Da Vinci Laan 15
1831 Diegem
Belgium

Marketing authorisation issued
25/09/2013
Withdrawal of marketing authorisation
15/11/2017
Revision
4

Assessment history

This page was last updated on

Share this page